[18F]FET PET imaging for early response assessment of bevacizumab in recurrent glioblastoma.

Background: F]FET PET) imaging and the relevance of the PET-based response assessment criteria for diffuse gliomas (PET RANO) criteria in assessing response to bevacizumab combination therapy in recurrent GBM. Methods: ) and associated changes were determined. Cox regression and receiver operating characteristic analyses were used to identify predictors of survival beyond the median overall survival (OS). Results: . Conclusion: F]FET PET for response assessment during bevacizumab treatment, the proposed response criteria improved identification of responders when compared with the PET RANO criteria. Nevertheless, further refinement and validation is needed to enhance PET-based response assessment.